Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence
Pharmaceuticals · 21.01.2026 · 19 (1) · 188
DOI: 10.3390/ph19010188 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 21.01.2026. Verfasst von Rafaela Guedes Pozzobon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Pesquisa Pelé Pequeno Príncipe, Av. Silva Jardim, 1632, Água Verde, Curitiba 80250-060, PR, Brazil. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Ministério da Saúde do Brasil, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil.
Abstract (Originalsprache)
Background
Ganoderma lucidum triterpenes are bioactive compounds with recognized anti-inflammatory, antitumor, and immunomodulatory properties. This systematic review synthesizes evidence regarding the anti-inflammatory activity of these triterpenes based on studies from the last two decades.
Methods
A systematic search was performed in PubMed, Medline, and Embase (2003–2025) for original in vitro and in vivo (non-clinical) studies evaluating G. lucidum triterpene extracts or isolated compounds. Clinical trials, reviews, and multi-species extracts were excluded. The review is registered on PROSPERO (CRD42024510982), and animal study quality was assessed using the SYRCLE Risk of Bias tool.
Findings
From over 3000 records, 23 articles were included. Studies utilized diverse models, including macrophages, human PBMCs, and various animal strains (mice, rats, chickens). All studies reported significant anti-inflammatory effects via reduction in pro-inflammatory markers (TNF-α, IL-1β, IL-6), primarily through downregulation of MAPK and TLR-4/NF-κB signaling pathways. Meta-analysis of in vitro data confirmed significant reductions in NO levels (−3.29 [95% CI: −5.21, −1.37]; p = 0.0008), IL-6 (−3.51 [−4.73, −2.29]; p < 0.00001), and TNF-α (−2.20 [−2.93, −1.48]; p < 0.00001). Similar anti-inflammatory profiles were observed in vivo across hepatic and splenic tissues.
Interpretation
Evidence consistently demonstrates the potent anti-inflammatory activity of G. lucidum triterpenes, highlighting their potential as therapeutic candidates for inflammatory diseases. However, the structural complexity and isomer diversity of these compounds remain significant barriers to pharmacological standardization. Future research must prioritize clinical translation by investigating compound synergism, bioavailability, and long-term toxicity profiles, which were notably absent in current non-clinical literature.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Pesquisa Pelé Pequeno Príncipe, Av. Silva Jardim, 1632, Água Verde, Curitiba 80250-060, PR, Brazil.
- Faculdades Pequeno Príncipe, Av. Iguaçu, 333, Rebouças, Curitiba 80230-020, PR, Brazil.
ORCID-Profile: Luíza Siqueira de Lima, Cláudia Sirlene Oliveira
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Ministério da Saúde do Brasil
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil
Zitieren
APA
Pozzobon, R. G., Rutckeviski, R., de Lima, L. S., Oliveira, C. S., & Smiderle, F. R. (2026). Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence. Pharmaceuticals, 19(1), 188. https://doi.org/10.3390/ph19010188
Vancouver
Pozzobon RG, Rutckeviski R, de Lima LS, Oliveira CS, Smiderle FR. Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence. Pharmaceuticals. 2026;19(1):188. doi:10.3390/ph19010188
BibTeX
@article{Pozzobon2026,
author = {Pozzobon, Rafaela Guedes and Rutckeviski, Renata and de Lima, Luíza Siqueira and Oliveira, Cláudia Sirlene and Smiderle, Fhernanda Ribeiro},
title = {Anti-Inflammatory Potential of Ganoderma lucidum Triterpenes: A Systematic Review and Meta-Analysis of Preclinical Evidence},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {1},
pages = {188},
doi = {10.3390/ph19010188}
}
EUVIMED